These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 26355674

  • 1. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.
    Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, Pappa K.
    AIDS; 2015 Nov 28; 29(18):2459-64. PubMed ID: 26355674
    [Abstract] [Full Text] [Related]

  • 2. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.
    N Engl J Med; 2013 Nov 07; 369(19):1807-18. PubMed ID: 24195548
    [Abstract] [Full Text] [Related]

  • 3. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M, ASSERT Team.
    Antivir Ther; 2013 Nov 07; 18(7):905-13. PubMed ID: 23899468
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE.
    J Infect Dis; 2011 Jun 15; 203(12):1791-801. PubMed ID: 21606537
    [Abstract] [Full Text] [Related]

  • 6. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
    Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Østergaard L, Langdahl BL, Laursen AL.
    PLoS One; 2012 Jun 15; 7(3):e32445. PubMed ID: 22479327
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.
    Farm Hosp; 2017 Sep 01; 41(5):601-610. PubMed ID: 28847249
    [Abstract] [Full Text] [Related]

  • 8. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, Brinkman K, Sabin CA, Reiss P, Mallon PW, PREPARE (Preventing Progression of Adipose Tissue Redistribution) Investigators.
    J Clin Endocrinol Metab; 2013 Apr 01; 98(4):1659-66. PubMed ID: 23436922
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C, Wohl D, Arribas JR, Henry K, Van Lunzen J, Bloch M, Towner W, Wilkins E, Ebrahimi R, Porter D, White K, Walker I, Chuck S, De-Oertel S, Fralich T.
    AIDS; 2014 Apr 24; 28(7):989-97. PubMed ID: 24508782
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F, Bouee S, Jeanbat V, Piontkowsky D, Aragao F, Bosse M.
    J Int AIDS Soc; 2014 Apr 24; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [Abstract] [Full Text] [Related]

  • 13. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
    Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA, DRIVE-AHEAD Study Group.
    Clin Infect Dis; 2019 Feb 01; 68(4):535-544. PubMed ID: 30184165
    [Abstract] [Full Text] [Related]

  • 14. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
    Haskelberg H, Hoy JF, Amin J, Ebeling PR, Emery S, Carr A, STEAL Study Group.
    PLoS One; 2012 Feb 01; 7(6):e38377. PubMed ID: 22719882
    [Abstract] [Full Text] [Related]

  • 15. Effect of Vitamin D Supplementation on Bone Turnover Markers During HIV Pre-Exposure Prophylaxis Using Tenofovir Disoproxil Fumarate-Emtricitabine in Men Who Have Sex with Men.
    Nanayakkara DD, Sun X, Morris S, Louie S, Mulligan K, Overton T, Asante I, Corado K, Jain S, Dubé MP.
    AIDS Res Hum Retroviruses; 2019 Jul 01; 35(7):608-614. PubMed ID: 30907095
    [Abstract] [Full Text] [Related]

  • 16. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, Pearce G.
    Antivir Ther; 2012 Jul 01; 17(6):1011-20. PubMed ID: 22910324
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.
    J Int AIDS Soc; 2014 Jul 01; 17(4 Suppl 3):19605. PubMed ID: 25394109
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
    Boontanondha P, Nimitphong H, Musikarat S, Ragkho A, Kiertiburanakul S.
    Curr HIV Res; 2020 Jul 01; 18(1):52-62. PubMed ID: 31906840
    [Abstract] [Full Text] [Related]

  • 19. Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).
    Hamzah L, Tiraboschi JM, Iveson H, Toby M, Mant C, Cason J, Burling K, Wandolo E, Jendrulek I, Taylor C, Ibrahim F, Kulasegaram R, Teague A, Post FA, Fox J.
    Antivir Ther; 2016 Jul 01; 21(4):287-96. PubMed ID: 26460504
    [Abstract] [Full Text] [Related]

  • 20. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
    DeJesus E, Ruane P, McDonald C, Garcia F, Sharma S, Corales R, Ravishankar J, Khanlou H, Shamblaw D, Ecker J, Ebrahimi R, Flaherty J, COMET Study Team.
    HIV Clin Trials; 2008 Jul 01; 9(2):103-14. PubMed ID: 18474495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.